SEARCH

SEARCH BY CITATION

Keywords:

  • antitumor agents;
  • bioinorganic chemistry;
  • DNA cleavage;
  • ligand design;
  • ruthenium

Abstract

Ruthenium(II) polypyridyl complexes with long-wavelength absorption and high singlet-oxygen quantum yield exhibit attractive potential in photodynamic therapy. A new heteroleptic RuII polypyridyl complex, [Ru(bpy)(dpb)(dppn)]2+ (bpy=2,2′-bipyridine, dpb=2,3-bis(2-pyridyl)benzoquinoxaline, dppn=4,5,9,16-tetraaza-dibenzo[a,c]naphthacene), is reported, which exhibits a 1MLCT (MLCT: metal-to-ligand charge transfer) maximum as long as 548 nm and a singlet-oxygen quantum yield as high as 0.43. Steady/transient absorption/emission spectra indicate that the lowest-energy MLCT state localizes on the dpb ligand, whereas the high singlet-oxygen quantum yield results from the relatively long 3MLCT(Ru→dpb) lifetime, which in turn is the result of the equilibrium between nearly isoenergetic excited states of 3MLCT(Ru→dpb) and 3ππ*(dppn). The dppn ligand also ensures a high binding affinity of the complex towards DNA. Thus, the combination of dpb and dppn gives the complex promising photodynamic activity, fully demonstrating the modularity and versatility of heteroleptic RuII complexes. In contrast, [Ru(bpy)2(dpb)]2+ shows a long-wavelength 1MLCT maximum (551 nm) but a very low singlet-oxygen quantum yield (0.22), and [Ru(bpy)2(dppn)]2+ shows a high singlet-oxygen quantum yield (0.79) but a very short wavelength 1MLCT maximum (442 nm).